Notably, in both solid tumor and blood cancer models, conventional CD19-targeting CAR-T cells were unable to fully eliminate tumor cells, leading to tumor relapse and ultimately, mouse mortality (Supplementary Fig. 11). This evidence concerns the gene CD19 and neoplasm.